nach oben

Annals of Nuclear Medicine

Erschienen in:

05.06.2019 | Original Article

¹⁸F-FDG PET/CT imaging in pulmonary sarcomatoid carcinoma and correlation with clinical and genetic findings

verfasst von: Xiaodong Wu, Yan Huang, Yuan Li, Qiang Wang, Huoqiang Wang, Lei Jiang

Erschienen in: Annals of Nuclear Medicine | Ausgabe 9/2019

Einloggen, um Zugang zu erhalten

Abstract

Objective

Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of non-small-cell lung cancer with poor prognosis. This study analyzed ¹⁸F-FDG PET/CT in PSC and possible correlations with the clinical and genetic findings.

Methods

Pre-operative ¹⁸F-FDG PET/CT findings and parameters of maximum standard uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) of primary lesion (MTV-P, TLG-P), and combination of primary lesion and metastases (MTV-C, TLG-C) were retrospectively analyzed in 24 patients with PSC confirmed by post-operative pathology. Tumor location, size, TNM stage, serum tumor markers, histopathological features, and mutations were also reviewed. Furthermore, progression-free survival (PFS) of 24 patients was analyzed.

Results

All 24 enrolled patients (20 men; 4 women; age: 62 ± 9 years) had single PSC, including 8 spindle cell carcinomas and 16 pleomorphic carcinomas. Serum levels of tumor markers were found to be abnormally increased sporadically. Six patients had central PSC, and 18 had peripheral PSC (diameter: 41 ± 16 mm). Eighteen lesions were located in the upper lobes of bilateral lungs, and 22 showed necrosis. Five cases were at TNM stage I, 12 at stage II, and 7 at stage III. The primary tumors were FDG avid in the 24 cases, with SUVmax of 17.2 ± 10.6. There were no correlations of SUVmax with tumor location, size, TNM stage, or histopathological subtypes. Programmed cell death ligand 1 (PD-L1) expression was detected in 21 cases (positivity rate: 87.5%). SUVmax of 17 lesions with PD-L1 expression degree ≥ 50% was obviously higher than that < 50% (P < 0.05). Kirsten rat sarcoma viral oncogene homolog (KRAS) gene mutation was found in six cases, and their SUVmax was significantly higher than that without KRAS mutation (P < 0.05). Furthermore, the median PFS of the 24 patients was 14 months, and 12-month and 24-month PFS rates were 55.9% and 27.8%, respectively. Only TLG-P and KRAS mutations of primary lesions were significantly associated with PFS.

Conclusions

PSC tended to present with intense ¹⁸F-FDG accumulation on PET/CT, and SUVmax was useful for assessing PD-L1 and KRAS expression of PSC. TLG-P and KRAS mutation were independent prognostic factors of PSC.

Nur mit Berechtigung zugänglich

Yendamuri S, Caty L, Pine M, Adem S, Bogner P, Miller A, et al. Outcomes of sarcomatoid carcinoma of the lung: a surveillance, epidemiology, and end results database analysis. Surgery. 2012;152:397–402.CrossRefPubMed

Gu L, Xu Y, Chen Z, Pan Y, Lu S. Clinical analysis of 95 cases of pulmonary sarcomatoid carcinoma. Biomed Pharmacother. 2015;76:134–40.CrossRefPubMed

Avila Martínez RJ, Marrón Fernández C, Hermoso Alarza F, Zuluaga Bedoya M, Meneses Pardo JC, Gámez García AP. Primary pulmonary sarcomatoid carcinoma. Arch Bronconeumol. 2013;49:405–7.PubMed

Paleiron N, Tromeur C, Gut-Gobert C, André N, Quiot JJ, Quintin-Roué I, et al. Pulmonary sarcomatoid carcinoma: clinical and prognostic characteristics, a case report. Rev Pneumol Clin. 2012;68:27–30.CrossRefPubMed

Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 world health organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10:1243–60.CrossRefPubMed

Takeuchi S, Khiewvan B, Fox PS, Swisher SG, Rohren EM, Bassett RL Jr, et al. Impact of initial PET/CT staging in terms of clinical stage, management plan, and prognosis in 592 patients with non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2014;41:906–14.CrossRefPubMed

Grootjans W, de Geus-Oei LF, Troost EG, Visser EP, Oyen WJ, Bussink J. PET in the management of locally advanced and metastatic NSCLC. Nat Rev Clin Oncol. 2015;12:395–407.CrossRefPubMed

Truong MT, Viswanathan C, Erasmus JJ. Positron emission tomography/computed tomography in lung cancer staging, prognosis, and assessment of therapeutic response. J Thorac Imaging. 2011;26:132–46.CrossRefPubMed

Anwar H, Vogl TJ, Abougabal MA, Grünwald F, Kleine P, Elrefaie S, et al. The value of different ¹⁸F-FDG PET/CT baseline parameters in risk stratification of stage I surgical NSCLC patients. Ann Nucl Med. 2018;32:687–94.CrossRefPubMed

10.

Ciarallo A, Makis W, Novales-Diaz JA, Lisbona R. Sarcomatoid carcinoma (carcinosarcoma) of the lung mimics malignant pleural mesothelioma on ¹⁸F-FDG PET/CT: a report of 2 cases. Clin Nucl Med. 2012;37:416–9.CrossRefPubMed

11.

Zhang Y, Li B, Shi H, Cai L, Gu Y. Sarcomatoid carcinoma of the lung mimics aspergilloma on ¹⁸F-FDG PET/CT. Hell J Nucl Med. 2015;18:268–70.PubMed

12.

Rapicetta C, Lococo F, Stefani A, Rossi G, Ricchetti T, Filice A, et al. Primary sarcomatoid carcinoma of the lung: radiometabolic ((¹⁸)F-FDG PET/CT) findings and correlation with clinico-pathological and survival results. Lung. 2016;194:653–7.CrossRefPubMed

13.

Jiang L, Tan H, Panje CM, Yu H, Xiu Y, Shi H. Role of ¹⁸F-FDG PET/CT imaging in intrahepatic cholangiocarcinoma. Clin Nucl Med. 2016;4:1–7.CrossRef

14.

Lin Y, Yang H, Cai Q, Wang D, Rao H, Lin S, et al. Characteristics and prognostic analysis of 69 patients with pulmonary sarcomatoid carcinoma. Am J Clin Oncol. 2016;39:215–22.CrossRefPubMed

15.

Sim JK, Chung SM, Choi JH, Oh JY, Lee SH, Kim JH, et al. Clinical and molecular characteristics of pulmonary sarcomatoid carcinoma. Korean J Intern Med. 2018;33:737–44.CrossRefPubMedPubMedCentral

16.

Martin LW, Correa AM, Ordonez NG, Roth JA, Swisher SG, Vaporciyan AA, et al. Sarcomatoid carcinoma of the lung: a predictor of poor prognosis. Ann Thorac Surg. 2007;84:973–80.CrossRefPubMed

17.

Shum E, Stuart M, Borczuk A, Wang F, Cheng H, Halmos B. Recent advances in the management of pulmonary sarcomatoid carcinoma. Expert Rev Respir Med. 2016;10:1–10.CrossRef

18.

Italiano A, Cortot AB, Ilie M, Martel-Planche G, Fabas T, Pop D, et al. EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: implications for anti-EGFR treatment of a rare lung malignancy. Int J Cancer. 2009;125:2479–82.CrossRefPubMed

19.

Mehrad M, Roy S, LaFramboise WA, Petrosko P, Miller C, Incharoen P, et al. KRAS mutation is predictive of outcome in patients with pulmonary sarcomatoid carcinoma. Histopathology. 2018;73:207–14.CrossRefPubMedPubMedCentral

20.

Lococo F, Gandolfi G, Rossi G, Pinto C, Rapicetta C, Cavazza A, et al. Deep sequencing analysis reveals that KRAS mutation is a marker of poor prognosis in patients with pulmonary sarcomatoid carcinoma. J Thorac Oncol. 2016;11:1282–92.CrossRefPubMed

21.

Takamochi K, Mogushi K, Kawaji H, Imashimizu K, Fukui M, Oh S, et al. Correlation of EGFR or KRAS mutation status with ¹⁸F-FDG uptake on PET-CT scan in lung adenocarcinoma. PLoS One. 2017;12:e0175622.CrossRefPubMedPubMedCentral

22.

Lee SM, Bae SK, Jung SJ, Kim CK. FDG uptake in non-small cell lung cancer is not an independent predictor of EGFR or KRAS mutation status: a retrospective analysis of 206 patients. Clin Nucl Med. 2015;40:950–8.CrossRefPubMed

23.

Minamimoto R, Jamali M, Gevaert O, Echegaray S, Khuong A, Hoang CD, et al. Prediction of EGFR and KRAS mutation in non-small cell lung cancer using quantitative ¹⁸F FDG-PET/CT metrics. Oncotarget. 2017;8:52792–801.CrossRefPubMedPubMedCentral

24.

Velcheti V, Rimm D, Schalper KA. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1). J Thorac Oncol. 2013;8:803–5.CrossRefPubMedPubMedCentral

25.

Lococo F, Torricelli F, Rossi G, Alifano M, Damotte D, Rapicetta C, et al. Inter-relationship between PD-L1 expression and clinic-pathological features and driver gene mutations in pulmonary sarcomatoid carcinomas. Lung Cancer. 2017;113:93–101.CrossRefPubMed

26.

Mu CY, Huang JA, Chen Y, Chen C, Zhang XG. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol. 2011;28:682–8.CrossRefPubMed

27.

Kasahara N, Kaira K, Bao P, Higuchi T, Arisaka Y, Erkhem-Ochir B, et al. Correlation of tumor-related immunity with ¹⁸F-FDG-PET in pulmonary squamous-cell carcinoma. Lung Cancer. 2018;119:71–7.CrossRefPubMed

28.

Liu J, Dong M, Sun X, Li W, Xing L, Yu J. Prognostic value of ¹⁸F-FDG PET/CT in surgical non-small cell lung cancer: a meta-analysis. PLoS One. 2016;11:e0146195.CrossRefPubMedPubMedCentral

29.

IeR Yoo, Chung SK, Park HL, Choi WH, Kim YK, Lee KY, et al. Prognostic value of SUVmax and metabolic tumor volume on ¹⁸F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis. Biomed Mater Eng. 2014;24:3091–103.

30.

Dosani M, Yang R, McLay M, Wilson D, Liu M, Yong-Hing CJ, et al. Metabolic tumour volume is prognostic in patients with non-small-cell lung cancer treated with stereotactic ablative radiotherapy. Curr Oncol. 2019;26:e57–63.CrossRefPubMedPubMedCentral

31.

Evangelista L, Cervino AR, Michieletto S, Saibene T, Ghiotto C, Guarneri V, et al. Diagnostic and prognostic impact of fluorine-18-fluorodeoxyglucose PET/CT in preoperative and postoperative setting of breast cancer patients. Nucl Med Commun. 2017;38:537–45.CrossRefPubMed

Titel: 18F-FDG PET/CT imaging in pulmonary sarcomatoid carcinoma and correlation with clinical and genetic findings
verfasst von: Xiaodong Wu
Yan Huang
Yuan Li
Qiang Wang
Huoqiang Wang
Lei Jiang
Publikationsdatum: 05.06.2019
Verlag: Springer Singapore
Erschienen in: Annals of Nuclear Medicine / Ausgabe 9/2019
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-019-01374-5

Springer Medizin

Abstract

Objective

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2019

Combining the radiomic features and traditional parameters of 18F-FDG PET with clinical profiles to improve prognostic stratification in patients with esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy and surgery

Development of visual scoring system with Tc-99m DMSA renal scintigraphy to predict the risk of recurrence of symptomatic urinary tract infections in pediatric patients

Prediction of occult lymph node metastasis using SUV, volumetric parameters and intratumoral heterogeneity of the primary tumor in T1-2N0M0 lung cancer patients staged by PET/CT

A reduced liver 18F-FDG uptake may be related to hypoalbuminemia in patients with malnutrition

Limited role of carbidopa-assisted 18F-FDOPA PET/CT in patients with sporadic non-functional gastroduodenal neuroendocrine neoplasms

18F-FDG PET/CT in visceral leishmaniasis: uptake patterns in the context of a multiannual outbreak in Northern Italy